Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.76 USD | +1.47% | -6.12% | -56.02% |
Apr. 23 | Top Premarket Decliners | MT |
Apr. 01 | T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2022 | 22.3M | Sales 2023 | 7.19M | Capitalization | 25.42M |
---|---|---|---|---|---|
Net income 2022 | -62M | Net income 2023 | -50M | EV / Sales 2022 | 2.66 x |
Net Debt 2022 | 48.89M | Net Debt 2023 | 33.81M | EV / Sales 2023 | 8.23 x |
P/E ratio 2022 |
-0.12
x | P/E ratio 2023 |
-0.33
x | Employees | 113 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 11.77% |
Latest transcript on T2 Biosystems, Inc.
1 day | +1.47% | ||
1 week | -8.91% | ||
Current month | -8.00% | ||
1 month | -3.83% | ||
3 months | -35.36% | ||
6 months | -47.02% | ||
Current year | -56.02% |
Managers | Title | Age | Since |
---|---|---|---|
John Sperzel
CEO | Chief Executive Officer | 60 | 20-01-07 |
John Sprague
DFI | Director of Finance/CFO | 65 | 18-01-29 |
Roger Smith
CTO | Chief Tech/Sci/R&D Officer | 59 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Elsbree
BRD | Director/Board Member | 76 | 14-06-30 |
Seymour Liebman
BRD | Director/Board Member | 74 | 16-09-20 |
Robin Toft
BRD | Director/Board Member | 63 | 20-06-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.76 | +1.47% | 329,459 |
24-04-23 | 2.72 | -13.92% | 359,187 |
24-04-22 | 3.16 | +6.76% | 1,363,736 |
24-04-19 | 2.96 | -1.00% | 534,565 |
24-04-18 | 2.99 | +1.70% | 106,827 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-56.02% | 23.92M | |
+8.78% | 219B | |
+8.24% | 187B | |
+11.16% | 134B | |
+26.12% | 101B | |
+0.30% | 62.27B | |
+16.21% | 52.82B | |
-1.63% | 47.49B | |
-1.11% | 40.79B | |
+12.16% | 39.35B |
- Stock Market
- Equities
- TTOO Stock